
This observational study compared denosumab and oral bisphosphonates for managing osteoporosis in dialysis-dependent patients, using data from a Japanese claims database. Over a 3-year follow-up, denosumab significantly reduced the risk of fractures by 45%, with a weighted 3-year risk ratio of 0.55. However, it also increased the risk of major adverse cardiac events (MACE) by 36%, with a weighted 3-year risk ratio of 1.36. These findings suggest denosumab may be more effective for fracture prevention but could raise cardiovascular risks, warranting further research.
Like
Save
Share